@article{article, title  = {{A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2019}},

 month = {{5}},

 author = {{Powles T and Meeks JJ and Galsky MD and Van Der Heijden MS and Nishiyama H and Al-Ahmadie H and Gupta AK and Ye J and Donegan SE and Ghiorghiu DC and Ferro S et al}},

 doi = {{10.1200/jco.2019.37.15_suppl.tps4592}},

 volume = {{37}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{TPS4592-TPS4592}},

 note = {{Accessed on 2024/12/22}}}